View Older Stories View More Recent Stories
-
RBC Capital on Stryker (SYK): 'Positive Takeaways from CEO Meeting at AAOS'
-
Piper Sandler: 'Stryker (SYK) Expected To Benefit From Strong Market Growth'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Stryker (SYK) launches Steri-Shield 8 personal protection system
-
Stryker (SYK) launches Sync Badge
-
Citi Starts Stryker (SYK) at Buy
-
Kadant (KAI) to Join S&P SmallCap 600
-
Stryker (SYK) Announces Retirement of Allan Golston from Board
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $413 at Truist Securities
-
Stryker (SYK) PT Raised to $440 at Stifel
-
RBC Capital on Stryker (SYK): 'We are Bullish on SYK's Durability of Growth'; PT Raised to $435
-
Stryker (SYK) PT Raised to $416 at BTIG
-
Stryker (SYK) PT Raised to $440 at Bernstein After a 'Strong Finish'
-
Stryker (SYK) to Sell U.S. spinal implants business, announces plans to sell related international business
-
Stryker (SYK) Announces CFO Change
-
Stryker (SYK) Tops Q4 EPS by 14c; offers guidance
-
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Inari Medical, Inc. (NARI)
-
Stryker (SYK) commences tender offer for all outstanding shares of common stock of Inari Medical
-
BTIG Downgrades Inari Medical Inc. (NARI) to Neutral
-
TD Cowen on Stryker (SYK): 'We Are Positive on SYK's Plan to Acquire NARI'
-
BofA Securities Reiterates Buy Rating on Stryker (SYK)
-
Inari Medical Inc. (NARI) PT Raised to $80 at Piper Sandler Following Acquisition Agreement with Stryker (SYK)
-
Evercore ISI Reiterates Outperform Rating on Stryker (SYK)
-
Stifel on Inari Medical Inc. (NARI): 'Quick Thoughts on the Deal and PEN Implications'
-
After-hours movers: Ulta Beauty, Inari Medical, Meta Platforms and more
-
Stryker (SYK) to acquire Inari Medical (NARI) for $80 Per Share, $4.9 Billion
-
Stryker (SYK) Nearing A Deal To Buy Inari Medical (NARI) , Sources Say - Reuters
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Stryker (SYK) PT Raised to $442 at Needham, added to Conviction List
-
RBC on Stryker (SYK): 'We are incrementally more positive on SYK's durable growth story'; PT Raised
-
Stryker (SYK) Raises Quarterly Dividend 5% to $0.84; 0.9% Yield
-
Morgan Stanley Upgrades Stryker (SYK) to Overweight
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Piper Sandler Reiterates Overweight Rating on Stryker (SYK)
-
Stryker (SYK) PT Raised to $380 at Truist Securities
-
Stryker (SYK) PT Raised to $420 at Piper Sandler
-
Stryker (SYK) PT Raised to $411 at Citi
-
Stryker (SYK) PT Raised to $400 at Canaccord Genuity
-
Stryker (SYK) PT Raised to $394 at BTIG
-
Stryker (SYK) Tops Q3 EPS by 10c; offers guidance
-
Stryker (SYK) call put ratio 1.3 calls to 1 put into quarter results and outlook
-
Vague Midwest Boutique Channel-Check Firm Comments Circulate Via Traders on Three Stocks
-
Treace Medical Concepts (TMCI) Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty® Bunion Technology
-
Piper Sandler Reiterates Overweight Rating on Stryker (SYK)
-
Stryker (SYK) completes acquisition of NICO
-
Stryker (SYK) completes acquisition of care.ai
-
Stryker (SYK) Expands Foot & Ankle Portfolio With Specialized Offerings Designed to Enhance Surgical Precision and Outcomes
-
Piper Sandler Reiterates Overweight Rating on Stryker (SYK)
